Gender-specific outcomes in immune checkpoint inhibitor therapy for advanced or metastatic urothelial cancer: a systematic review and meta-analysis

[1] Aragaki AK(2022)Gender-specific stratification of survival following immune checkpoint inhibitor therapy based on intratumoral expression of a B cell gene signature Eur Urol Oncol 5 338-346

[2] Jing Y(2021)Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma N Engl J Med 384 2102-2114

[3] Hoffman-Censits J(1981)Plasma catecholamines, insulin and glucose in the postoperative phase. Cause and duration of the post-stress syndrome after abdominal surgery Chirurg 52 225-230

[4] Choi W(2017)Pembrolizumab as second-line therapy for advanced urothelial carcinoma N Engl J Med 376 1015-1026

[5] Hahn NM(2021)Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial Lancet Oncol 22 525-537

[6] Trock BJ(2017)The role of gender-specific cytokine pathways as drug targets and gender—specific biomarkers in personalized cancer therapy Curr Drug Targets 18 485-495

[7] Bajorin DF(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-442

[8] Witjes JA(2013)Epidemiology and risk factors of urothelial bladder cancer Eur Urol 63 234-241

[9] Gschwend JE(2018)Sexual dimorphism of immune responses: a new perspective in cancer immunotherapy Front Immunol 9 552-31

[10] Schenker M(2014)Sex differences in incidence and mortality of bladder and kidney cancers: national estimates from 49 countries Urol Oncol 32 e23-197

[1] Aragaki AK(2022)Gender-specific stratification of survival following immune checkpoint inhibitor therapy based on intratumoral expression of a B cell gene signature Eur Urol Oncol 5 338-346

[2] Jing Y(2021)Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma N Engl J Med 384 2102-2114

[3] Hoffman-Censits J(1981)Plasma catecholamines, insulin and glucose in the postoperative phase. Cause and duration of the post-stress syndrome after abdominal surgery Chirurg 52 225-230

[4] Choi W(2017)Pembrolizumab as second-line therapy for advanced urothelial carcinoma N Engl J Med 376 1015-1026

[5] Hahn NM(2021)Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial Lancet Oncol 22 525-537

[6] Trock BJ(2017)The role of gender-specific cytokine pathways as drug targets and gender—specific biomarkers in personalized cancer therapy Curr Drug Targets 18 485-495

[7] Bajorin DF(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-442

[8] Witjes JA(2013)Epidemiology and risk factors of urothelial bladder cancer Eur Urol 63 234-241

[9] Gschwend JE(2018)Sexual dimorphism of immune responses: a new perspective in cancer immunotherapy Front Immunol 9 552-31

[10] Schenker M(2014)Sex differences in incidence and mortality of bladder and kidney cancers: national estimates from 49 countries Urol Oncol 32 e23-197